Company Announcements

28 May 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of Results, Investor Presentation, and AGM

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited results for the year ended 31 December 2023 ("Full Year Results") and Annual Report 2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 10 June 2024, 16:30 BST (08:30 Pacific time).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 June 2024, 09:00 BST (01:00 Pacific time), or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via: https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.

A full overview of the 2023 fiscal year will be presented in the Annual Report 2023, which will be available on the Company's website on 7 June 2024. at: www.ondinebio.com/investors/reports-documentation/. The slides and recording of the live presentation will be posted to the same webpage as soon as available following the presentation, no later than 11 June 2024.

The Company's 2024 Annual General Meeting is being held virtually on 28 June 2024 at 16:00 BST (08:00 Pacific time); registered shareholders and their duly appointed proxyholders can attend the Meeting online via the link being provided in the Notice of Meeting.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave ™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.